Published on March 19, 2013 at 11:50 AM
The test will be unveiled during the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 (Athena Diagnostics Booth 1413). At the conference, Athena Diagnostics will also introduce several new clinical lab-developed tests for a range of rare neurological disorders, including hereditary neuropathy and neuromuscular disease.
About Athena Diagnostics
Athena Diagnostics is a leader in diagnostic testing for neurological diseases and offers innovative tests for Alzheimer's disease, muscular dystrophy and other neuromuscular and developmental disorders. Athena, a division of Quest Diagnostics, is dedicated to providing neurologists and other physicians and specialists with insights that can improve patient health. Athena provides the most comprehensive test menu and intellectual property portfolio for neurological, endocrine, and renal conditions through more than 400 diagnostic tests. For more information, visit www.athenadiagnostics.com.
About Quest Diagnostics
Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com or follow us at Facebook.com/Quest Diagnostics and Twitter.com/QuestDX.
Quest, Quest Diagnostics, Athena Diagnostics and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics.